Table of Contents
Kingston Health Sciences Centre in Ontario has launched a regulated clinical trial examining whether psilocybin-assisted therapy can reduce anxiety. The trial is in an early enrollment phase, and no outcome data have been reported yet. No conclusions about effectiveness can be drawn at this stage.
- A Canadian institution is now running this work: Kingston Health Sciences Centre in Ontario is among the first Canadian hospital-based sites to open enrollment for a psilocybin anxiety trial under a regulated framework.
- This is a clinical trial, not an approved treatment: Participation is controlled, monitored, and limited to enrolled volunteers. Psilocybin remains a controlled substance in Canada outside of authorized exemptions.
- No outcome data are available yet: The Global News report covers the trial launch and enrollment, not results. Any therapeutic claims would be premature.
- Regulatory authorization was required: Conducting this trial in Canada required specific federal authorization, reflecting how carefully controlled this line of research remains.
- Model
- human
- Sample
- Enrolling (number not specified in source)
- Dose
- Not specified in source
- Design
- Clinical trial, details not specified in source
- Key outcome
- Trial is in enrollment phase; no outcome data reported
- Main limitation
- Source is a news article covering trial launch, not peer-reviewed findings
What the Research Examined
The source for this entry is a Global News report published in October 2025 covering the launch of a clinical trial at Kingston Health Sciences Centre in Ontario. Because the source is a news article rather than a published study, this recap covers what the article reports about the trial’s existence and design. No peer-reviewed results, participant numbers, dosing protocols, or outcome measures were included in the source text. That distinction matters: we are reporting on a trial opening its doors, not on findings from a completed study.
The trial is described as using psilocybin in a therapeutic context to address anxiety, conducted within a regulated Canadian framework that required federal authorization. Kingston Health Sciences Centre is the named institutional host. The broader context of psilocybin-assisted therapy research has grown steadily in recent years, with trials at institutions in the United States, the United Kingdom, and now visibly in Canada, each working under their respective regulatory structures to build an evidence base the field currently lacks at scale.
Until the underlying study protocol is published or registered data become available, the most accurate thing that can be said is this: a regulated Canadian hospital is now enrolling people to study psilocybin’s effects on anxiety. That is meaningful as a signal of institutional momentum, and it is the limit of what the source supports.
What the Findings Show
- Trial location.Kingston Health Sciences Centre, Ontario, Canada, as reported by Global News.
- Target condition.Anxiety, as described in the news report. No diagnostic subtype was specified in the source.
- Trial status.Active enrollment, per the October 2025 news report. No interim or final outcome data were described.
Because the source is a news article about a trial launch and not a published study, there are no quantitative findings to report. The numbers that matter most, such as sample size, dose, response rates, and follow-up duration, are not available in the source. Readers interested in the trial’s registered protocol may wish to search ClinicalTrials.gov or Health Canada’s clinical trials database for the Kingston Health Sciences Centre psilocybin study once registration details are made public.
Is there a psilocybin clinical trial for anxiety in Canada?
Yes. As of October 2025, Kingston Health Sciences Centre in Ontario is conducting a regulated clinical trial examining psilocybin-assisted therapy for anxiety. The trial is in the enrollment phase, and no results have been published. Participation requires formal enrollment and federal authorization applies.
What This Is, and What It Is Not
This is This entry is based on a news article reporting the launch of a clinical trial, not on peer-reviewed data or a published study protocol.
This is not This is not evidence that psilocybin treats or cures anxiety, and it should not be read as medical advice or as an endorsement of any particular course of action. No dose, response rate, or efficacy finding has been reported from this trial.
Our Take
There is something quietly significant about a Canadian hospital opening its doors to this work. For years, psilocybin-assisted therapy existed at the margins of mainstream medicine, studied in small pilots and defended in academic papers. A regulated trial at an established health sciences centre in Ontario signals that the conversation has shifted. For this community, where psilocybin is understood as a sacrament whose potential for healing is inseparable from intention and care, the arrival of institutional science is welcome, provided that the humanity of the experience is not reduced to a data point. We will follow this trial and report on its findings when they emerge.
If this trial stirs something in you, whether curiosity, hope, or a wish to understand more about how psilocybin affects the anxious mind, you are in the right place. The Church of Psychedelics exists to hold both the science and the sacred together, without collapsing one into the other. Grounding comes first: knowing what the research actually says, stripped of hype and of fear, before any deeper work begins. Browse, ask questions, and come back when the findings arrive. We will be here.
Frequently Asked Questions
What is the psilocybin anxiety trial in Kingston, Ontario?
Kingston Health Sciences Centre in Ontario launched a regulated clinical trial in 2025 to study whether psilocybin-assisted therapy can reduce anxiety. The trial is in the enrollment phase. No results have been reported. Federal authorization was required to conduct the research in Canada.
Is psilocybin legal for clinical trials in Canada?
Psilocybin remains a controlled substance in Canada, but Health Canada can grant special authorization for regulated research. This Kingston trial operates under such an authorization. Outside of approved research or exemption programs, psilocybin is not legally available in Canada.
How can I enroll in a psilocybin clinical trial for anxiety?
Eligibility and enrollment details vary by trial and are set by the research team. To find registered trials, search ClinicalTrials.gov or Health Canada’s clinical trials database. Never self-medicate based on trial reports. Speak with a licensed health-care provider before pursuing any clinical participation.
What does psilocybin-assisted therapy for anxiety involve?
In published research from other institutions, psilocybin-assisted therapy typically combines one or a small number of supervised psilocybin sessions with preparation and integration talk therapy. The specific design of the Kingston trial was not described in the source article.
Are there any results from this Ontario psilocybin trial yet?
No. As of the October 2025 news report, the trial had recently opened enrollment and no outcome data had been published. Results from clinical trials are typically shared through peer-reviewed journals after the study is complete and data are analyzed.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
